Sarah James: Thank you. I was hoping to drill into the selling season a little bit more. First on the memory, the $1.3 million is a lot better than consensus was looking for, but it also implies about 1,000 lives per client uptick, so reversing the dip in 2023. How do you think about that trending forward? And then I was hoping you could also walk us through the math on the new client ads. I understand some of the 85 decided to start early, but I’m trying to bridge the 460 to where we are now and the 85 ads.
Pete Anevski: I’ll do the second part of the question first. It’s a weird echo. I’ll do the second part of the question first. So relative to bridging the new client ads versus the expected clients for next year, what we’ve seen this year is much more normal than we’ve seen in prior years, if you exclude last year. New client starts during the year are small clients not having any meaningful contribution to incremental revenue relative to existing clients, but in terms of client counts, do start earlier and this year was no different. So if you just take the existing clients that we just reported that we’re live with and take the 85 and subtract the delta in the math of what we are saying for next year, that’s roughly how many new clients with a small amount of lives each have already launched this year.
As it relates to the average per client, we sort of say this every year in our sales years, it’s not a perfect science relative to who you add in which year and whether they’re bigger or smaller, we try and win all of them and the averages sort of play out. I think the more relevant point for us in terms of where we’re at relative to our addressable market is that there is plenty of opportunity relative to large and small clients that we can still go after and will and so the averages will play out whether they bounce around plus or minus a thousand as you point out in a given year, we sort of don’t focus on that as much, we focus on winning as many as we can.
Sarah James: Great and second question here is on your partnerships. It’s really exciting to see the announcements ramp up this quarter. How should we think about the pipeline potential for future partnership and how do you think about that materiality to your revenue growth?
Pete Anevski: Yes, I mean partners play a significant role in both pipeline activity as well as obviously closed and committed clients and business and we would expect that trend to continue. We’re excited about the partnerships that we added this year. It’s early in sort of the first year so we would expect those partnerships to continue to evolve and continue to increase in their impact and then, the new partnerships around FIFTIA [Ph] Health and the opportunity to partner with, our first, large regional health plan and importantly collaborating with them to offer the Progyny solution to clients of all sizes relative to the prior question. We’re excited about that. We sort of don’t go into detail on partner by partner of what that impact will be, but we’re pleased with the ads of these new partnerships, especially since, especially on the health plan side, we really just started, recently focusing in that area.
Sarah James: Great, thank you.
Operator: Thank you. Your next question is coming from Richard Close from Canaccord. Your line is live.
Richard Close: Yes, thanks for the questions and congratulations. Pete, I was just wondering if you could talk a little bit about the not now and your thoughts about that. I mean, I know you talked about benefit changes and GLP-1s and just curious in terms of how much of a change that was this year during the selling season and thought process as these not nows go into the pipeline and opportunity to convert them next year.
